Pantesin® pantethine improves blood lipids in adults at low to moderate risk of cardiovascular disease, study shows
- Pantesin® pantethine lowers risk markers in men and women with low or moderate CVD risk.
- Effective dosage is 600 mg/day (weeks 1 to 8), then 900 mg/day (weeks 9 to 16)
- Treatment significantly (P<.05) reduces total, LDL-, and non-HDL-cholesterol at 16 weeks, compared to placebo
This randomized, double-blind, placebo-controlled study involved 32 middle-aged men and women living in North America at low- or moderate-risk of cardiovascular disease (CVD) and eligible for statin therapy based on the National Cholesterol Education Program (NCEP) guidelines.
Subjects followed a Therapeutic Lifestyle Change (TLC) diet for 4 weeks before starting the study and maintained the diet throughout a 16-week study period. The subjects were randomly assigned to take Pantesin® HF pantethine (600 mg/day from weeks 1 to 8 and 900 mg/day from weeks 9 to 16) or a placebo.
Compared to placebo, treatment significantly (P<.05) reduced total cholesterol (at 16 weeks), LDL cholesterol (at 8 and 16 weeks), and non-HDL cholesterol (at 16 weeks). A significant between-group difference in LDL cholesterol was found as early as week 8. These findings suggest that pantethine lowers CVD risk markers in people with low or moderate CVD risk.
PANTESIN® is a registered trademark of Daiichi Fine Chemical Co., Ltd.